Bull or Bear Market… Doesn’t matter

Kyle Dennis’ new, 5 Min Strategy is poised to double Your Money Weekly!

Michael S. made 173% with Dollar Ace. So can you!


On the Watch: Catalyst Pharmaceuticals (CPRX)

Kyle DennisKyle Dennis ·

The setup: Catalyst Pharmaceuticals (CPRX) has been forecasting a fourth-quarter Phase 3 data release for its drug Firdapse in treatment of a rare autoimmune disease, Lambert-Eaton Myasthenic Syndrome (LEMS). Based on the timing of the beginning and end of trial enrollment, I expect that Phase 3 data to come in December.

How I’m playing it: Right now, the chart is making a nice triangle continuation pattern. It closed Friday at $2.75, and I think it’s a good buy somewhere in the $2.60 to $2.70 region, for a potential run back up to 52-week highs of about $3.15.

How I evaluate catalysts: I’m an event-driven trader, but some catalysts are more compelling than others. I look for three factors: the specific date of a data release, the disease indication being trialed, and the size of the company.

  • Specific dates make a difference, because more people are interested in playing a stock if they know exactly when data is coming out. That’s why I am watching Eiger BioPharmaceuticals (EIGR), because we know their next release is at the J.P. Morgan healthcare conference. See why Kyle is watching Eiger Biopharmaceuticals (EIGR)
  • Treatments for rare diseases like LEMS, or incurable conditions — like cancer or Alzheimer’s disease — are strong catalysts. Drugs for chronic conditions like arthritis are less exciting to traders and don’t work as well.
  • The size of the company matters too; multi-billion-dollar companies like Bristol-Myers Squibb Co.  (BMY) don’t move much on drug-trial data. If a small company hits well on their drug, it means a ton for their stock; likewise, if the drug fails, the consequences could be severe. The best catalyst runs tend to occur when the risk is high and the stakes are higher.


Kyle Dennis runs Kyle Dennis’ Biotech Breakouts (biotechbreakouts.com). He is an event-based trader, who prefers low-priced and small-cap biotech stocks. He has no stocks, options or open orders in CPRX but day-traded it on Oct. 27 for a small loss.

You may also like

Exclusive System Tracks Wall St. Insiders

“Dollar Ace Simply Exposes Information That Wall Street Wants To Keep Quiet” Said Kyle Dennis
“One member, Wesley M., has already reported 360%+ gains in just a few short days. Don’t miss this!”
(Reserve Access Now)

“What Recession?!” Jason Bond nets $55,060 in realized profit in One Day

After going 6 for 6 on profitable trades recently, we caught up with Jason to ask how he did it.
Check out Jason’s exclusive interview revealing this tightly guarded strategy. (Watch Now)

RagingBull.com Co-Founder, Jeff Bishop, Launches High Conviction Trade Service

“We listen to our clients and we give them EXACTLY what they want, so we designed a service to deliver 1 trade, 1 time a week, with a 100%+ PROFIT TARGET, directly to your inbox every Monday before the market opens. (Read More)

Be a Better Stock Trader, Starting Today

Get the expert insights, tips and strategies you need to optimize your trading skills and profiles